Reverse DCF
What growth does the market imply for THYROCARE?
Working backwards from the current price to find the FCF growth assumption baked in.
reasonable
18.2% implied annual FCF growth
The market's growth assumption looks achievable — it is in line with or below what this company has historically delivered.
Current Price
₹529
Historical Growth
18.0%
FCF Yield
2.29%
Price / FCF
43.8x
Plain English
To justify today's price of ₹528.90, THYROCARE.NS needs to grow its free cash flow at 18.2% per year for the next 10 years. That is 0.2% faster than its historical growth rate of 18.0%. This looks achievable — the market is not pricing in heroic assumptions. There may be genuine upside if the company executes.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Half implied | 9.1% | ₹261 | -50.6% |
| GDP rate | 10.0% | ₹280 | -47.0% |
| Historical | 18.0% | ₹519 | -1.9% |
| Implied | 18.2% | ₹529 | +0.0% |
At Historical Growth Rate
DCF horizon: 10 years. At 18.0% growth, the model values THYROCARE at ₹519, below today's ₹529.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, reverse DCF, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.